Study: CBD-Derived Compound Shows Potential to Treat Bladder Dysfunction After Spinal Cord Injury
- The study found that CIAC001, a cannabidiol-derived compound, may help treat bladder dysfunction caused by spinal cord injury by reducing neuroinflammation and promoting nerve repair.
- Researchers tested CIAC001 on female mice with severe spinal cord injuries, observing improvements in bladder function, structure, and neural pathways related to urination.
- Spinal cord injury caused significant bladder issues and neuroinflammation, which CIAC001 treatment notably reduced, including decreasing bladder weight and harmful astrocytes.
- The findings suggest CIAC001 as a promising candidate for treating neurogenic bladder dysfunction post-spinal cord injury, though further studies are needed to confirm effects in humans.
A new study published in Life Sciences found that a cannabidiol-derived compound may help treat bladder dysfunction caused by spinal cord injury by reducing neuroinflammation and helping restore damaged nerve pathways. The research was conducted by scientists from Air Force Medical University and the Hunan Institute of Science and Technology, both in China. Researchers focused on a compound known as CIAC001, a small molecule derived from cannabidiol, or CBD. According to the study, the compound has already shown anti-neuroinflammatory effects, leading researchers to examine whether it could improve neurogenic lower urinary tract dysfunction, a common complication following spinal cord injury.
To test this, researchers used female mice with severe spinal cord injuries at the T9 level and treated one group with daily doses of CIAC001 for 28 days. They then measured bladder function, kidney-related markers, bladder structure, voiding behavior, and changes in the spinal cord and brain pathways involved in urinary control.
The study found that spinal cord injury caused substantial bladder problems, including enlarged bladders, increased bladder weight, thinning of the detrusor muscle, more frequent voiding spots, and impaired bladder pressure and emptying. Researchers also found significant neuroinflammation in the spinal cord, along with weaker neural connections between the bladder and key brain regions involved in urination.
CIAC001 treatment significantly improved many of these issues. The compound reduced bladder weight, improved several urodynamic measures, lowered signs of neuroinflammation, reduced harmful A1 astrocytes, and appeared to support axonal regeneration. Researchers also found evidence that it helped rebuild bladder-related neural pathways.
The study concludes that CIAC001 “effectively ameliorates key symptoms of SCI-induced NLUTD in mice,” primarily by suppressing neuroinflammation and helping facilitate neural repair. Researchers say the findings identify the compound as a promising candidate for treating neurogenic bladder dysfunction after spinal cord injury, although further research will be needed to determine whether the results translate to humans.